The White House proposed a rule to disclose drug prices in consumer ads. Individuals familiar with the proposal said that drugmakers would need to reveal a drug’s list price in DTC ads. (Axios)
The FDA is launching a study of the listing in DTC ads of safety risks and side effects. The agency wants to measure how well consumers understand the risks and if the ads “overwarn” them. (STAT)
FDA approves Shire’s HAE drug. Takhzyro treats hereditary angioedema, a rare and life-threatening genetic condition. It’s expected to generate $1.3 billion in peak annual sales. (Endpoints News)
Makers of e-cigarette and vape liquids that resemble children’s juice boxes have stopped selling them. The FDA announced yesterday that 17 makers will stop selling them. The agency had issued a warning to manufacturers in May. (New York Times)
Gilead sells shelved drug to Sierra Oncology for $3 million: Gilead paid $510 million for momelotinib, originally envisioned as a treatment for a bone marrow condition, five years ago, but shelved it in 2016 after mixed trial results. Sierra Oncology plans to test it as an anemia treatment. (CNBC)
